<DOC>
	<DOCNO>NCT02190149</DOCNO>
	<brief_summary>This 6-month prospective outcome study address association time infusion , patient activity level , bleed episode patient-reported measurement .</brief_summary>
	<brief_title>Study Prophylaxis , ACtivity Effectiveness ( SPACE ) Hemophilia Patients Currently Treated With ADVATE RIXUBIS</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>13 65 year old time screen moderately severe severe hemophilia A B ( FVIII/FIX level ≤2 % ) , without transient inhibitor Hemophilia A patient currently prescribe ADVATE ( FVIII ) Hemophilia B patient currently prescribe RIXUBIS ( FIX ) previously treat plasmaderived FVIII/FIX concentrate recombinant FVIII/FIX ≥150 document exposure day ( EDs ) willing able comply requirement protocol proficient English language allow use SPACE eDiary inhibitor titer ≥0.6 Bethesda unit currently treat inhibitor participate another clinical study involve medicinal product device within 30 day prior enrollment schedule participate another clinical study involve medicinal product device course study family member employee investigator elective major surgery plan within 6 month enrollment may interfere activity daily live ( investigator 's discretion ) continuously require walk assistance device ( eg , wheelchair , crutch , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
	<keyword>Factor FIX Deficiency</keyword>
</DOC>